• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Actelion gains on Sanofi deal rumors

December 16, 2016 By Sarah Faulkner

Actelion gains on Sanofi deal rumorsActelion (VTX:ATLN) shares jumped more than 8% to 214 Swiss francs after reports that Sanofi (NYSE:SNY) and the Swiss biotech are nearing a takeover deal that would value Actelion at $29.6 billion.

After Johnson & Johnson (NYSE:JNJ) abandoned its efforts to reach an agreement with Actelion this week, Sanofi stepped in to pursue negotiations. Sanofi is expected to offer Actelion shareholders cash plus contingent value rights, according to Bloomberg. Investors told Reuters that they would push for more information if Sanofi makes such an offer.

The French drugmaker is eager to land a deal after it lost out on Medivation Inc. earlier this year, which gave Pfizer its blockbuster Xtandi prostate cancer drug. A $26.9 billion deal with Actelion would top Sanofi’s $20.1 billion purchase of rare disease specialist Genzyme in 2011.

Actelion’s portfolio includes drugs for pulmonary arterial hypertension and the company plans to expand into mutliple sclerosis and clostridium difficile. Some investors would prefer to take the cash from a takeover deal rather than bet on CEO Jean-Paul Clozel’s risky pipeline.

“If I look at the (drugs) pipeline that Mr. Clozel is excited about, I am perhaps less excited about it and see perhaps a greater risk than reward,” Union Bancaire Privee fund manager Eleanor Taylor Jolidon told Reuters.

But Clozel has repeatedly maintained that the company should remain independent. In 2011, he rallied shareholders against an investor’s bid to sell the company and 4 years later he fought off interest from drugmaker Shire.

As the pricetag for Actelion continues to climb, investors have said that if Clozel rejects a reasonable bid, then “he would have a lot of explaining to do.”

Filed Under: Featured, Mergers & Acquisitions, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Sanofi-Aventis

IN CASE YOU MISSED IT

  • Biden’s COVID-19 response will make manufacturers busy
  • Mylan must face EpiPen racketeering lawsuit
  • EmblemHealth to provide coverage for Senseonics’ Eversense CGM
  • Eitan Medical lands FDA clearance for infusion pump system upgrade
  • Senseonics announces $50M from stock offering

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS